HF
ALLO icon

HRT Financial’s Allogene Therapeutics ALLO Stock Holding History

HRT Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.53M Buy
3,621,579
+3,601,974
+18,373% +$7.91M 0.01% 918
2026
Q1 		$47K Sell
19,605
-53,146
-73% -$107K ﹤0.01% 3462
2025
Q4 		$99K Sell
72,751
-59,780
-45% -$78.9K ﹤0.01% 2791
2025
Q3 		$164K Buy
+132,531
New +$158K ﹤0.01% 2451
2024
Q1 		– Sell
-235,333
Closed -$755K – 2243
2023
Q4 		$755K Buy
+235,333
New +$667K 0.01% 1130
2023
Q2 		– Sell
-104,172
Closed -$514K – 2403
2023
Q1 		$514K Buy
+104,172
New +$668K 0.01% 1361
2022
Q4 		– Sell
-110,259
Closed -$1.19M – 2423
2022
Q3 		$1.19M Buy
+110,259
New +$1.5M 0.01% 816
2022
Q1 		– Sell
-10,675
Closed -$159K – 3032
2021
Q4 		$159K Buy
+10,675
New +$188K ﹤0.01% 2616
2021
Q2 		– Sell
-36,018
Closed -$1.27M – 2794
2021
Q1 		$1.27M Buy
+36,018
New +$1.21M 0.01% 921

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial's ALLO Position: Q2 2026 in Review

HRT Financial increased its Allogene Therapeutics (ALLO) stake by 18,373% in Q2 2026, buying an estimated $7.91M and bringing the position to 3,621,579 shares worth $7.53M. The position accounts for 0.01% of the portfolio, ranked #918.

HRT Financial first reported a position in ALLO in Q1 2021 and has held it in 9 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • HRT Financial held 3,621,579 shares of Allogene Therapeutics worth $7.53M as of Q2 2026.
  • HRT Financial bought 3,601,974 Allogene Therapeutics shares in Q2 2026, an estimated $7.91M.
  • Allogene Therapeutics made up 0.01% of HRT Financial's portfolio in Q2 2026, its #918 holding.
  • HRT Financial first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.